VLS Valneva SE

Valneva SE - Declaration of voting rights - December 2025

Valneva SE - Declaration of voting rights - December 2025

VALNEVA

Declaration of shares and voting rights

December 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: Îlot Saint Joseph Bureaux Convergence – 12T Quai Perrache – 69002 Lyon

Regulated market of Euronext Paris - Compartment B

Declaration date: January 8, 2026

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 



 



173,539,745



ordinary shares with a par value of €0.15 each		189,428,384Double voting rights granted on 3,412 ordinary shares



 



Transfer into bearer form of 4,895 shares with double voting rights



 



Exercise of stock options resulting in the issuance of 429,317 new ordinary shares



 



Definitive attribution of 255,218 free ordinary shares		Between December 1 & December 27, 2025



 



Between December 1 & December 27, 2025



 



Between December 1 & December 5, 2025



 



 



On December 15, 2025		189,304,062

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
08/01/2026

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Christophe-Raphaël Ganet ... (+3)
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SCR SCOR SE
ASY ASSYSTEM SA
SWP SWORD GROUP SE
AUB AUBAY SA
VLS VALNEVA SE
ATE ALTEN SA
TPE PVA TEPLA AG
NEX NEXANS SA
CAP CAPGEMINI SE
SOI SOITEC SA
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
AALB AALBERTS N.V.
MELE MELEXIS NV
ALSN ALSO HOLDING AG
ECONT ECONOCOM GROUP SE CLASS D
UNI UNICAJA BANCO S.A.
NKT NKT A/S
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
TOM2 TOMTOM NV
NA9 NAGARRO
HGEA HGEARS AG
ALVGO VOGO SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
02/04/26 February 4, 2026 1 EN
Christophe-Raphaël Ganet ... (+3)
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Thomas Zlowodzki
SOP SOPRA STERIA GROUP SA
ACN ACCENTURE PLC CLASS A
INF INFOTEL SA
SCR SCOR SE
ASY ASSYSTEM SA
SWP SWORD GROUP SE
AUB AUBAY SA
VLS VALNEVA SE
ATE ALTEN SA
TPE PVA TEPLA AG
NEX NEXANS SA
CAP CAPGEMINI SE
SOI SOITEC SA
MTELEKOM MAGYAR TELEKOM TELECOMMUNICATIONS
VRNL VERNEUIL PARTICIPATIONS
CTAC CTAC N.V.
COK CANCOM SE
BC8 BECHTLE AG
ADN1 ADESSO AG
AALB AALBERTS N.V.
MELE MELEXIS NV
ALSN ALSO HOLDING AG
ECONT ECONOCOM GROUP SE CLASS D
UNI UNICAJA BANCO S.A.
NKT NKT A/S
REY REPLY S.P.A.
AEIN ALLGEIER HOLDING AG
WAVE WAVESTONE SA
TOM2 TOMTOM NV
NA9 NAGARRO
HGEA HGEARS AG
ALVGO VOGO SA
AROBS AROBS TRANSILVANIA SOFTWARE SA
IOS IONOS GROUP SE
ATO ATOS SE
02/04/26 February 4, 2026 1 FR
Martial Descoutures
  • Martial Descoutures
VLS VALNEVA SE

Valneva : What is at stake for VLA15 in Lyme disease?

After particularly promising phase II results in Lyme disease, unveiled at end-2025, we see the stock offering an attractive risk/reward profile ahead of the phase III results for VLA15 expected in the coming weeks. In a high-potential segment with no competition, VLA15 boasts a unique position, now central to Valneva's development and valuation momentum. We maintain our Outperform rating, with an adjusted target price of € 8.1 vs € 7.

02/04/26 February 4, 2026 1 EN
Martial Descoutures
  • Martial Descoutures
VLS VALNEVA SE

Valneva : Quel est l’enjeu de VLA15 dans la maladie de Lyme?

Suite aux résultats de phase?2 particulièrement prometteurs dans la maladie de Lyme, dévoilés fin 2025, nous voyons un risque / reward attractif sur le titre en amont des résultats de phase 3 de VLA15 attendus dans ces prochaines semaines. Dans un segment de marché au potentiel élevé et où la concurrence demeure inexistante, VLA15 occupe ainsi une position unique, désormais centrale dans la dynamique de développement et de valorisation de Valneva. Nous réitérons notre recommandation à Surperform...

02/04/26 February 4, 2026 1 FR
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccinat...

Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ® Lyon (France), Sao Paulo, (Brazil), February 3, 2026 –  (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and Instituto Butantan, one of the world’s largest biomedical research centers, today announced the initiation of a Pilot Vaccination Strategy (PVS) in Brazil using Valneva’s single-shot chikungunya vaccine, IXCHIQ®. The pilot vaccination program will serve as the basis for post-marketing commitment studies evaluating the effectiveness ...

February 3, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch